{"id":"W4319066709","doi":"10.1016/j.eclinm.2023.101826","title":"Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study","year":2023,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; Innovaderm (Canada)","funders":"Kiniksa Pharmaceuticals","keywords":"Prurigo nodularis; Medicine; Atopy; Dermatology; Population; Placebo; Atopic dermatitis; Dupilumab; Internal medicine; Immunopathology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002552946,0.0004281818,0.002463298,0.0006457504,0.0001612364,0.00001668983,0.0002297474,0.0002709067,0.0004523915],"category_scores_gemma":[0.002602357,0.0003020653,0.0002264683,0.0008478424,0.0003310531,0.00009334269,0.0001712164,0.0006890376,0.0001199136],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004676161,"about_ca_system_score_gemma":0.0002793143,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007476822,"about_ca_topic_score_gemma":0.00004569665,"domain_scores_codex":[0.9952964,0.000468213,0.002225515,0.0008208833,0.0006261117,0.0005628544],"domain_scores_gemma":[0.9955583,0.002628643,0.0003751325,0.0006415299,0.0002041334,0.0005922711],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.914479,0.006673225,0.06457177,0.0001999887,0.0006980989,0.0009340621,0.00149617,0.0001117765,0.0007231215,0.0000299191,0.008311025,0.001771804],"study_design_scores_gemma":[0.9461906,0.00347517,0.04517114,0.0008041211,0.000717831,0.00006473644,0.001012481,0.00130802,0.00008449786,0.00008726231,0.0007686446,0.0003154875],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851353,0.0004813551,0.00007964807,0.004860313,0.000254421,0.008098075,0.00005005714,0.0001472313,0.0008935726],"genre_scores_gemma":[0.9966516,0.0002280999,0.0002496344,0.0008330697,0.0002609093,0.000475045,0.0003997036,0.00005428345,0.000847648],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03171157,"threshold_uncertainty_score":0.9999431,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05024678208822447,"score_gpt":0.4160109102661748,"score_spread":0.3657641281779503,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}